Table 2.

Results of the cost-utility analysis

Parameter	Ruconest®	Berinert® P
Quality-adjusted life years (QALY) in comparison to placebo (median)*	0.0261 QALY	0.0262 QALY
Total incremental costs in comparison to placebo (median)**	EUR 419.27# (PLN 1,719)	EUR 754.63# (PLN 3,094)
Incremental Cost-Utility Ratio (ICUR) in comparison to placebo (median)	EUR 15,225.61per QALY# (PLN 62,425 per QALY)	EUR 27,786.34# per QALY (PLN 113,924.00 per QALY)
Percentage of simulations where treatment option was cost-effective in comparison to placebo	64%	41%

^*p = 0.346, medians were not significantly different

^**p < 0.0001, medians were significantly different

^#assuming that EUR 1 = PLN 4.10